Invivyd, Inc. (NASDAQ:IVVD) Receives $5.14 Average Target Price from Brokerages

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.3875.

Several analysts have recently commented on IVVD shares. D. Boral Capital raised their target price on Invivyd from $1.00 to $2.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a report on Friday. Cantor Fitzgerald initiated coverage on Invivyd in a research note on Monday, October 6th. They issued an “overweight” rating and a $10.00 price objective for the company. HC Wainwright boosted their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday. Finally, Zacks Research cut Invivyd from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 15th.

Invivyd Stock Down 5.9%

Invivyd stock opened at $1.76 on Friday. The company has a market capitalization of $377.36 million, a PE ratio of -1.91 and a beta of 0.63. Invivyd has a 12-month low of $0.35 and a 12-month high of $2.74. The firm’s fifty day moving average is $1.41 and its 200 day moving average is $0.98.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The company had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million. Sell-side analysts expect that Invivyd will post -1.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Invivyd news, insider Jill Andersen sold 49,402 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the transaction, the insider directly owned 84,446 shares of the company’s stock, valued at approximately $48,134.22. This trade represents a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 277,654 shares of company stock worth $167,215 in the last 90 days. Corporate insiders own 25.40% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of Invivyd in the 1st quarter worth about $66,000. Invesco Ltd. increased its holdings in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Invivyd in the first quarter worth approximately $65,000. AQR Capital Management LLC lifted its holdings in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after purchasing an additional 28,146 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.